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Abstract
Aims and Hypothesis—We hypothesize that transcription factor 7-like 2 (TCF7L2) single
nucleotide polymorphisms (SNPs) are associated with cardiovascular disease (CVD) and that the
associations differ in diabetic and non-diabetic participants.
Methods—Black and white subjects from the Atherosclerosis Risk in Communities (ARIC)
study who were free of prevalent CVD at baseline and genotyped for rs7903146, rs12255372,
rs7901695, rs11196205, and rs7895340 were included in this analysis (n = 13,369). Cox
proportional hazard regression was used to estimate the associations of polymorphisms and
incident events and logistic and linear regression were used for associations with baseline risk
factor levels.
Results—TCF7L2 SNPs were not significantly associated with incident coronary heart disease,
ischemic stroke, CVD, prevalent peripheral artery disease (PAD), or with all-cause mortality in
the full cohort or stratified by race.
Conclusions/Interpretation—In the whole cohort, TCF7L2 SNPs were not associated with
incident CVD, all-cause mortality, or prevalent PAD. This result suggests that the increased health
risk associated with rs7903146 genotype is specific to diabetes.
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Introduction
Diabetes is a major risk factor for stroke, peripheral artery disease (PAD), and coronary
heart disease (CHD). Transcription factor 7-like 2 (TCF7L2) polymorphisms have been
associated with diabetes in numerous studies[1–3] and the magnitude of risk conferred by
TCF7L2 variants is greater that for any previously described common variant. The single
nucleotide polymorphism (SNP) rs7903146 is the most highly associated of the known
variants and is associated with a 40% increased risk of diabetes per allele[4]. The gene
TCF7L2 is located on chromosome 10 and encodes the transcription factor Tcf-4. Of
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particular interest, a specific role for Tcf-4 has been shown in the process of vascular
remodeling. Moreover, transcriptional activation of Tcf-4 turns on the NF-kB signaling
pathway, which regulates inflammatory signaling pathways[5]. Data from the MONICA/
KORA Surveys showed the T allele of rs7903146 was inversely associated with homeostasis
model assessment of percent β-cell function (HOMA-%B) and fasting insulin suggesting a
role in pancreatic beta cell function[3]. Support for this hypothesis is seen in cell culture
experiments and other human studies. Depleting islet cells of TCF7L2 in culture resulted in
significant increases in beta-cell apoptosis and decreases in proliferation and glucose
stimulated insulin secretion[6]. Therefore, we hypothesize that TCF7L2 SNPs would be
associated with cardiovascular disease (CVD) in the Atherosclerosis Risk in Communities
(ARIC) Study. Furthermore, we investigated whether the associations of TCF7L2 genotypes
with CVD differ in diabetic and non-diabetic participants.
Subjects, materials, and methods
The ARIC study is a prospective cohort study of 15,792 participants investigating the
etiology of atherosclerosis and described in detail elsewhere[7]. For this analysis,
individuals were excluded based on the following criteria; race other than black or white
(n=48), blacks from centers with small numbers (n=55), prevalent CHD (n=763), missing
data for prevalent CHD (n=339), prevalent stroke (n=264), and missing genotype data for
TCF7L2 SNP rs7903146 (n=954). The final analysis sample included 13,369 subjects. For
the investigation with PAD, individuals missing ankle brachial index were further excluded
(n=457). Ascertainment and standardized case definitions for PAD[8], CHD[9], stroke[10],
carotid intimal medial thickness (IMT)[11], mortality[12], and diabetes[13] have been
described elsewhere. Five TCF7L2 SNPs were genotyped on stored DNA using the
TaqMan® System; rs7903146, rs12255372, rs7901695, rs11196205, and rs7895340
(www.appliedbiosystems.com.). Five percent of samples were re-genotyped for quality
control and 726 ARIC participants were genotyped in duplicate. The percentage of
agreement was 96% and simple Kappa coefficient was 0.93 indicating good genotype
quality. All data were analyzed with SAS, Version 9 (SAS Institute Inc., Cary, NC). We
tested for Hardy Weinberg equilibrium using the χ2 goodness of fit test. Cox proportional
hazard regression was used to estimate the associations of SNPs and incident events and
logistic and linear regression were used for baseline prevalence measures. We had 80%
power to detect a relative risk of 1.17 for incident CHD with an alpha = 0.05.
Results
The study population included 27% blacks, 57% were female, and the mean age was 54
years. All 5 SNP genotype frequencies were in Hardy-Weinberg equilibrium. The following
results focus on rs7903146. Baseline diabetes, current smoking, life-time smoking exposure
(pack-years), and BMI (kg/m2) differed by genotype. For the CC, CT and TT genotypes
respectively, the baseline prevalence of diabetes was 9.4%, 12.2%, and 14.2% (p<0.0001)
and the percentage of current smokers was 25%, 26%, and 28% (p=0.03). The T-allele was
associated with lower mean BMI (CC=27.8, CT=27.5, TT=27.4 kg/m2, p=0.03) and more
pack-years of smoking (CC=14.7, CT=15.2, and TT=16.3, p=0.05). There was no difference
by genotype for age, race, sex, current drinking, ethanol intake, waist-to-hip ratio, total
cholesterol, HDL and LDL cholesterol, triglycerides, or systolic and diastolic blood
pressure.
The T-allele of rs7903146 was not significantly associated with incident CHD, ischemic
stroke, or CVD, or with all-cause mortality in the full cohort or stratified by race (Table 1).
In whites with prevalent diabetes, the T-allele was associated with incident CHD but only in
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the model adjusted for age, sex, BMI, and smoking status (HR = 1.21, p = 0.04). We found
no significant association of this allele with prevalent PAD or IMT (data not shown).
Discussion
We hypothesized that TCF7L2 SNPs would be associated with increased risk of CVD and
all-cause mortality given the association of these variants with diabetes. In the whole cohort,
rs7903146 was not associated with incident CVD, all-cause mortality, or prevalent PAD.
The T-allele of rs7903146 was associated with smoking and inversely associated with BMI
in the whole cohort and in a subset of whites with prevalent diabetes this allele was
associated with incident CHD. Results from the Go-Darts Study of over 6,500 European
subjects reported the T-allele was associated with increased hemoglobin A1c (HbA1c) in
both cases and controls. These researchers also reported that the T-allele was
overrepresented in individuals requiring insulin treatment and underrepresented in patients
managed by diet alone suggesting that variants of TCF7L2 may be associated with disease
severity and therapeutic efficacy[14]. Therefore, a reasonable hypothesis is that the small
increased risk of CHD seen in our study may be the result of suboptimal or ineffective
treatment of diabetes in the earlier onset cases. However, the increased risk observed in the
white subgroup was not seen in the corresponding black group (HR = 1.04, 95% CI = 0.79–
1.36). While the association may be spurious given that this was one of several subgroup
analyses, the inconsistency between races may result from the smaller sample size in this
racial group. In prevalent diabetics, we had 80% power to detect a relative risk of 1.54 and
1.78 for incident CHD in whites and blacks respectively. Clearly, replication in a larger and
possibly younger diabetic population is needed to confirm or refute this finding.
In their entirely, these results suggest that while there may be a slight increased risk of CHD
in early onset diabetes cases, the increased health risk associated with rs7903146 genotype is
specific to diabetes.
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